GLENMARK LIFE SCIENCES LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 842.6 INR | +2.02% |
|
-0.36% | +28.23% |
| May. 15 | Granules India posts Q4 revenue fall on weak paracetamol sales, price erosion | RE |
| Apr. 25 | Transcript : Glenmark Life Sciences Limited, Q4 2024 Earnings Call, Apr 25, 2024 |
Valuation
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 56,215 | 48,141 | 103,235 | - | - |
| Enterprise Value (EV) 1 | 51,123 | 45,047 | 92,145 | 100,733 | 101,305 |
| P/E ratio | 12.9 x | 10.3 x | 20.2 x | 18.9 x | 16.5 x |
| Yield | 2.29% | 5.34% | 2.9% | 2.61% | 2.8% |
| Capitalization / Revenue | 2.63 x | 2.23 x | 4.17 x | 4.02 x | 3.52 x |
| EV / Revenue | 2.39 x | 2.08 x | 4.04 x | 3.92 x | 3.45 x |
| EV / EBITDA | 8.1 x | 7.01 x | 13.7 x | 12.8 x | 11.2 x |
| EV / FCF | 11.3 x | 31.5 x | 32.4 x | 45.2 x | 36.3 x |
| FCF Yield | 8.85% | 3.18% | 3.09% | 2.21% | 2.76% |
| Price to Book | - | 2.25 x | 4.09 x | 3.85 x | 3.36 x |
| Nbr of stocks (in thousands) | 122,527 | 122,527 | 122,527 | - | - |
| Reference price 2 | 458.8 | 392.9 | 842.6 | 842.6 | 842.6 |
| Announcement Date | 4/20/22 | 4/27/23 | 4/25/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 18,852 | 21,379 | 21,612 | 22,832 | 25,674 | 29,333 |
| EBITDA 1 | - | 6,308 | 6,423 | 6,742 | 7,861 | 9,070 |
| EBIT 1 | - | 5,929 | 6,002 | 6,208 | 7,339 | 8,414 |
| Operating Margin | - | 27.73% | 27.77% | 27.19% | 28.59% | 28.68% |
| Earnings before Tax (EBT) 1 | - | 5,649 | 6,286 | 6,313 | 7,434 | 8,415 |
| Net income 1 | - | 4,187 | 4,670 | 4,709 | 5,467 | 6,258 |
| Net margin | - | 19.59% | 21.61% | 20.62% | 21.29% | 21.33% |
| EPS 2 | - | 35.63 | 38.11 | 38.38 | 44.57 | 51.03 |
| Free Cash Flow 1 | - | 4,524 | 1,432 | 2,845 | 2,227 | 2,794 |
| FCF margin | - | 21.16% | 6.63% | 12.46% | 8.67% | 9.53% |
| FCF Conversion (EBITDA) | - | 71.73% | 22.3% | 42.2% | 28.33% | 30.81% |
| FCF Conversion (Net income) | - | 108.05% | 30.67% | 60.43% | 40.74% | 44.65% |
| Dividend per Share 2 | - | 10.50 | 21.00 | 22.50 | 21.98 | 23.58 |
| Announcement Date | 7/20/21 | 4/20/22 | 4/27/23 | 4/25/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,638 | 5,260 | 5,192 | 4,994 | 5,093 | 5,407 | 6,213 | 5,784 | 5,980 | 6,025 | 6,070 |
| EBITDA 1 | - | 1,496 | - | 1,468 | 1,436 | 1,455 | 2,064 | 1,932 | 2,012 | 1,693 | 1,702 |
| EBIT 1 | 1,598 | 1,399 | 1,378 | 1,464 | 1,437 | 1,413 | 1,949 | 1,824 | 1,947 | - | 1,708 |
| Operating Margin | 28.33% | 26.59% | 26.53% | 29.31% | 28.22% | 26.13% | 31.37% | 31.53% | 32.56% | - | 28.14% |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | - | - | 1,820 | - | - | 1,729 |
| Net income 1 | - | 1,037 | - | 1,087 | 1,069 | 1,050 | 1,464 | 1,354 | 1,419 | 1,182 | 1,176 |
| Net margin | - | 19.72% | - | 21.77% | 20.99% | 19.42% | 23.56% | 23.42% | 23.73% | 19.62% | 19.36% |
| EPS 2 | - | - | - | - | - | - | - | 11.05 | - | - | 10.40 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 2/8/22 | 4/20/22 | 8/4/22 | 10/21/22 | 1/27/23 | 4/27/23 | 7/21/23 | - | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 5,093 | 3,094 | 3,016 | 2,502 | 1,930 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 4,524 | 1,432 | 2,845 | 2,227 | 2,794 |
| ROE (net income / shareholders' equity) | - | 29.8% | 22.3% | 21.1% | 21.6% | 21.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 175.0 | 190.0 | 219.0 | 251.0 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 1,452 | 1,702 | 1,290 | 3,350 | 2,750 |
| Capex / Sales | - | 6.79% | 7.87% | 5.65% | 13.05% | 9.38% |
| Announcement Date | 7/20/21 | 4/20/22 | 4/27/23 | 4/25/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
842.6
INR
Average target price
932.6
INR
Spread / Average Target
+10.69%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +28.23% | 1.21B | |
| +54.61% | 815B | |
| +44.25% | 654B | |
| -6.33% | 354B | |
| +20.62% | 337B | |
| +10.44% | 302B | |
| +18.45% | 247B | |
| +2.09% | 229B | |
| +13.03% | 219B | |
| +8.61% | 171B |
- Stock Market
- Equities
- GLS Stock
- Financials Glenmark Life Sciences Limited
